OncoMatch/Clinical Trials/NCT04871607
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
Is NCT04871607 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for recurrent hodgkin lymphoma.
Treatment: Basiliximab · Carmustine · Cytarabine · Etoposide · Genetically Engineered Hematopoietic Stem Progenitor Cells · Recombinant Granulocyte Colony-Stimulating Factor · Yttrium Y 90 Basiliximab — This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory) or has come back (relapsed). Yttrium-90-labeled anti-CD25 is an antibody (proteins made by the immune system to fight infections) that is attached to a radioactive substance and may kill cancer cells and shrink tumors. Chemotherapy drugs, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Prior therapy
Must have received: salvage cytoreductive chemotherapy
Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to ≤ grade 2 (CTCAE v5)
Must have received: autologous hematopoietic progenitor cell collection
Patients will be enrolled after collection of at least 2.0 x 10^6 CD34 cells/kg of autologous hematopoietic progenitor cells (HPC-A) by apheresis
Cannot have received: high dose chemotherapy with autologous stem cell transplant
Prior high dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation
Cannot have received: allogeneic transplantation
Prior high dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation
Cannot have received: external beam radiation therapy
Exception: Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records by the Radiation Oncology PI
Significant prior external beam dose-limiting radiation to a critical organ
Cannot have received: planned brentuximab vedotin consolidation after AHCT
Planned BV consolidation after AHCT
Cannot have received: concurrent investigational agents, biological, chemotherapy, or radiation therapy
Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
Lab requirements
Kidney function
Serum creatinine ≤ 1.5 mg/dL; Creatinine clearance of ≥ 60 mL/min per 24 hour urine test
Liver function
Total bilirubin ≤ 1.5 X ULN (unless has Gilbert's disease); AST/SGOT ≤1.5 x ULN (except in cases where abnormal LFTs are due to involvement with HL); ALT/SGPT ≤ 1.5 x ULN (except in cases where abnormal LFTs are due to involvement with HL)
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%
Serum creatinine ≤ 1.5 mg/dL; Creatinine clearance of ≥ 60 mL/min per 24 hour urine test; Total bilirubin ≤ 1.5 X ULN (unless has Gilbert's disease); AST/SGOT ≤1.5 x ULN (except in cases where abnormal LFTs are due to involvement with HL); ALT/SGPT ≤ 1.5 x ULN (except in cases where abnormal LFTs are due to involvement with HL); Left ventricular ejection fraction (LVEF) ≥ 50%; FEV1 > 65% of predicted measured, or DLCO (diffusion capacity) ≥ 50% of predicted measured (corrected for hemoglobin)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify